Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECOX: Oxaliplatin and Capecitabine plus Sorafenib in Advanced HCC
NCT01245582Phase 3Withdrawn
- Sponsor
- Sanofi
- Start
- Jul 2011
- Primary completion
- Feb 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 3 trial of oxaliplatin, capecitabine in hepatocellular carcinoma (HCC), sponsored by Sanofi. Planned start Jul 2011; status: withdrawn.
02
Drugs
oxaliplatincapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01245582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01245582.